1. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis 
Ying Liu, Timothy Vollmer, Eva Havrdova, Katherine Riester, Andrew Lee, Glenn Phillips, Ping Wang, Guido Sabatella 
Multiple Sclerosis and Related Disorders 
Volume 11, Pages (January 2017)
DOI: /j.msard
Copyright © 2016 The Authors Terms and Conditions

2. Fig. 1
Percentage of patients with clinically meaningful worsening in patient-reported physical impact of MS (≥7.5-point worsening in MSIS-29 PHYS score) by study visit. Estimated from a logistic model adjusted for baseline MSIS-29 PHYS score, baseline Beck Depression Inventory-II score, prior IFN beta use (yes, no), and baseline age (≤35, >35 years). a Percent reduction in odds of clinically meaningful worsening. IFN, interferon; IM, intramuscular; MS, multiple sclerosis; MSIS-29, 29-item Multiple Sclerosis Impact Scale; PHYS, physical impact subscale..
Multiple Sclerosis and Related Disorders  , 18-24DOI: ( /j.msard )
Copyright © 2016 The Authors Terms and Conditions

3. Fig. 2
Mean change from baseline in MSIS-29 score over time for the (a) MSIS-29 PHYS and (b) MSIS-29 PSYCH. p values represent between-treatment differences and were estimated based on an analysis of covariance model adjusting for baseline MSIS-29 PHYS (or PSYCH) score, baseline Beck Depression Inventory-II score, prior IFN beta use (yes, no), and baseline age (≤35, >35 years). Error bars represent the standard error of the mean. IFN, interferon; IM, intramuscular; MSIS-29, 29-item Multiple Sclerosis Impact Scale; PHYS, physical impact subscale; PSYCH, psychological impact subscale..
Multiple Sclerosis and Related Disorders  , 18-24DOI: ( /j.msard )
Copyright © 2016 The Authors Terms and Conditions

4. Fig. 3
Change from baseline in percentage of patients reporting not at all bothered at week 96 for the (a) MSIS-29 PHYS and (b) MSIS-29 PSYCH. IFN, interferon; IM, intramuscular; MS, multiple sclerosis; MSIS-29, 29-item Multiple Sclerosis Impact Scale; PHYS, physical impact subscale; PSYCH, psychological impact subscale..
Multiple Sclerosis and Related Disorders  , 18-24DOI: ( /j.msard )
Copyright © 2016 The Authors Terms and Conditions

5. Fig. 4
Mean change from baseline in the (a) EQ-5D health utility index and (b) EQ-5D VAS score. p values represent between-treatment differences and were estimated based on an analysis of covariance model adjusting for baseline EQ-5D health index (or VAS) score, baseline Beck Depression Inventory-II score, prior IFN beta use (yes, no), and baseline age (≤35, >35 years). Error bars represent the standard error of the mean. EQ-5D, EuroQol 5-Dimensions; IFN, interferon; IM, intramuscular; VAS, visual analog scale..
Multiple Sclerosis and Related Disorders  , 18-24DOI: ( /j.msard )
Copyright © 2016 The Authors Terms and Conditions